PMCUF (Health Care Technology) Stock Valuation & Fair Value Significantly overvalued
PMCUF (Health Care Technology) trades at a blended P/E of 121.4, about 9% above its historical normal valuation, with a forward growth estimate of 31.5% and a PEG of 3.85. Analysts' one-year estimates have been hit 60% of the time.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.
Valuation flags
- High PEG (3.9x)
Verdict history
tickerseer's rating has been significantly overvalued since 2026-09-19.
Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.
Frequently asked questions
Is PMCUF overvalued?
At a blended P/E of 121.4 versus its historical normal P/E of 111.2, PMCUF trades about 9% above its typical valuation, with a PEG of 3.85 on 31.5% forward growth. tickerseer currently rates it significantly overvalued.
What is PMCUF's fair value and PEG?
PMCUF trades at a blended P/E of 121.4 against a historical normal P/E of 111.2, a PEG of 3.85, and a forward growth estimate of 31.5%.
Has tickerseer's rating of PMCUF changed?
tickerseer's rating has been significantly overvalued since 2026-09-19.
Industry: Health Care Technology. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.